Bao Pharma-B Completes HK$1.99 Million Share Buyback, Outstanding Shares Fall to 152.29 Million

Bulletin Express

09/01

Shanghai Bao Pharmaceuticals Co., Ltd. (Bao Pharma-B) disclosed that it repurchased 119,200 H-shares on 1 September 2026 via on-exchange transactions, paying an aggregate HK$1.99 million. The shares were bought at prices ranging between HK$16.48 and HK$16.81, implying a volume-weighted average cost of HK$16.73 per share.

Following the transaction, the company’s issued share capital (excluding treasury shares) decreased by 0.08% to 152.29 million shares. Concurrently, treasury stock rose to 2.04 million shares, while the total number of issued shares remained unchanged at 154.33 million.

The repurchase forms part of the 10% buyback mandate approved on 26 May 2026, which authorises the company to acquire up to 15.43 million shares. Cumulative repurchases under this mandate now stand at 2.04 million shares, representing 1.32% of the share count recorded on the mandate date.

Under Hong Kong listing rules, Bao Pharma-B is restricted from issuing, selling or transferring treasury shares for 30 days following the latest repurchase, setting the moratorium’s expiry on 1 October 2026.

Executive Director Liu Yanjun confirmed that all repurchases were executed in accordance with Hong Kong Stock Exchange requirements and the company’s stated repurchase programme.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/1100111680"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1100111680\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1100111680?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-01 18:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1100111680","market":"hk","top_or_hot":-1,"title":"Bao Pharma-B Completes HK$1.99 Million Share Buyback, Outstanding Shares Fall to 152.29 Million","media":"Bulletin Express","content":"<p>Shanghai Bao Pharmaceuticals Co., Ltd. (Bao Pharma-B) disclosed that it repurchased 119,200 H-shares on 1 September 2026 via on-exchange transactions, paying an aggregate HK$1.99 million. The shares were bought at prices ranging between HK$16.48 and HK$16.81, implying a volume-weighted average cost of HK$16.73 per share.</p>\n<p>Following the transaction, the company’s issued share capital (excluding treasury shares) decreased by 0.08% to 152.29 million shares. Concurrently, treasury stock rose to 2.04 million shares, while the total number of issued shares remained unchanged at 154.33 million.</p>\n<p>The repurchase forms part of the 10% buyback mandate approved on 26 May 2026, which authorises the company to acquire up to 15.43 million shares. Cumulative repurchases under this mandate now stand at 2.04 million shares, representing 1.32% of the share count recorded on the mandate date.</p>\n<p>Under Hong Kong listing rules, Bao Pharma-B is restricted from issuing, selling or transferring treasury shares for 30 days following the latest repurchase, setting the moratorium’s expiry on 1 October 2026.</p>\n<p>Executive Director Liu Yanjun confirmed that all repurchases were executed in accordance with Hong Kong Stock Exchange requirements and the company’s stated repurchase programme.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bao Pharma-B Completes HK$1.99 Million Share Buyback, Outstanding Shares Fall to 152.29 Million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBao Pharma-B Completes HK$1.99 Million Share Buyback, Outstanding Shares Fall to 152.29 Million\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time smaller\">2026-09-01 18:21</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Shanghai Bao Pharmaceuticals Co., Ltd. (Bao Pharma-B) disclosed that it repurchased 119,200 H-shares on 1 September 2026 via on-exchange transactions, paying an aggregate HK$1.99 million. The shares were bought at prices ranging between HK$16.48 and HK$16.81, implying a volume-weighted average cost of HK$16.73 per share.</p>\n<p>Following the transaction, the company’s issued share capital (excluding treasury shares) decreased by 0.08% to 152.29 million shares. Concurrently, treasury stock rose to 2.04 million shares, while the total number of issued shares remained unchanged at 154.33 million.</p>\n<p>The repurchase forms part of the 10% buyback mandate approved on 26 May 2026, which authorises the company to acquire up to 15.43 million shares. Cumulative repurchases under this mandate now stand at 2.04 million shares, representing 1.32% of the share count recorded on the mandate date.</p>\n<p>Under Hong Kong listing rules, Bao Pharma-B is restricted from issuing, selling or transferring treasury shares for 30 days following the latest repurchase, setting the moratorium’s expiry on 1 October 2026.</p>\n<p>Executive Director Liu Yanjun confirmed that all repurchases were executed in accordance with Hong Kong Stock Exchange requirements and the company’s stated repurchase programme.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02659","symbol_name":"寶濟藥業-B","start_time":0,"source_url":"","article_id":"1100111680","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1100111680","pubTimestamp":1788258102,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Shanghai Bao Pharmaceuticals Co., Ltd. (Bao Pharma-B) disclosed that it repurchased 119,200 H-shares on 1 September 2026 via on-exchange transactions, paying an aggregate HK$1.99 million. The shares...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02659":"宝济药业-B"},"translate_title":"宝医药B完成199万港元股份回购，流通股降至1.5229亿股","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02659":1},"content_text":"Shanghai Bao Pharmaceuticals Co., Ltd. (Bao Pharma-B) disclosed that it repurchased 119,200 H-shares on 1 September 2026 via on-exchange transactions, paying an aggregate HK$1.99 million. The shares were bought at prices ranging between HK$16.48 and HK$16.81, implying a volume-weighted average cost of HK$16.73 per share.\nFollowing the transaction, the company’s issued share capital (excluding treasury shares) decreased by 0.08% to 152.29 million shares. Concurrently, treasury stock rose to 2.04 million shares, while the total number of issued shares remained unchanged at 154.33 million.\nThe repurchase forms part of the 10% buyback mandate approved on 26 May 2026, which authorises the company to acquire up to 15.43 million shares. Cumulative repurchases under this mandate now stand at 2.04 million shares, representing 1.32% of the share count recorded on the mandate date.\nUnder Hong Kong listing rules, Bao Pharma-B is restricted from issuing, selling or transferring treasury shares for 30 days following the latest repurchase, setting the moratorium’s expiry on 1 October 2026.\nExecutive Director Liu Yanjun confirmed that all repurchases were executed in accordance with Hong Kong Stock Exchange requirements and the company’s stated repurchase programme.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}